unresectable, recurrent Esophageal Squamous Cell Carcinoma (ESCC)

DBCOND0145164Digestive System Diseases Neoplasms

unresectable, recurrent Esophageal Squamous Cell Carcinoma (ESCC) is the indication for 2 drugs in DrugBank. It is covered by 3 curated, structured indications.

Classified under: Digestive System Diseases
Neoplasms
Indicated drugs: Hyaluronidase (human recombinant)
Nivolumab

What you can answer from here — as of October 23, 2026

2Indicated drugsWith each drug's targets and mechanism

Listed above

3Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

1Drug reporting it as an adverse effectWith incidence where the label states it

Which approved drugs for unresectable, recurrent Esophageal Squamous Cell Carcinoma (ESCC) share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account